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ABSTRACT
OBJECTIVES: We investigated the changes in the IL-6 and STAT3 expression levels in cachectic and non-
cachectic patients with gastric, lung and breast cancer and evaluated the association between IL-6 and 
STAT3 levels and cancer types in terms of cachexia condition.
BACKGROUND: Cancer-associated cachexia, observed in nearly 50‒80 % of cancer patients, has drawn 
attention in advanced patients. IL-6/JAK/STAT pathway plays an essential role in the progression of cancer 
cachexia through the regulation of the infl ammatory response.
METHODS: This study consisted of 48 gastric, breast and lung cancer patients (18 cachectic and 30 non-
cachectic) and healthy individuals. Total RNA isolation and cDNA synthesis was performed after the collection 
of blood samples. IL-6 and STAT3 expression levels were analyzed by RT- PCR analysis. 
RESULTS: Our fi ndings demonstrated that IL-6 mRNA levels considerably increased 19.89±8.25, 5.18±2.81 
and 15.33±9.54-fold in gastric, lung and breast cancer patients with cachexia, respectively. Additionally, 
a 16.67±7.13, 14.21±11.72 and 8.85±3.89-fold increase in the STAT3 expression level was detected in 
cachectic gastric, lung and breast cancer patients, respectively (p<0.01). 
CONCLUSION: STAT3 may be considered as a therapeutic target for cachectic patients with gastric, lung 
and breast cancer. Furthermore, IL-6 mediates STAT3 activation in cachectic gastric and breast cancer 
patients (Tab. 5, Fig. 2, Ref. 62). Text in PDF www.elis.sk.
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Introduction
Cachexia, which accounts for 20 % cancer deaths, is a multi-
factorial syndrome and defi ned by weight loss > 5 % or > 2 % 
with a body mass index (BMI) < 20 kg/m2 over 6 months and the 
loss of skeletal muscle (< 7.26 kg/m2 for males and < 5.45 kg/m2 
for females), adipose tissue and skeletal muscle mass. Therefore, 
cachexia is associated with a poor prognosis, toxicities, reduces 
overall survival and thus, cachexia has a negative impact on the 
quality of life in cancer patients. Furthermore, no benefi cial effects 
are observed with parenteral nutrition and supplementation to treat 
cachectic cancer patients due to anorexia, anemia and systemic 
infl ammation (1‒6). 
The interleukin 6 (IL-6) mediated Janus Kinase (JAK)/ Signal 
transducer and activator of transcription 3 (STAT3) pathway play 
an important role in cancer cachexia through induction of systemic 
infl ammatory response (7, 8). STAT3 is a transcription factor and 
aberrant activation of the phosphorylated STAT3 (pSTAT3) is in-
volved in nearly 70 % of human cancers due to promoting tumor 
growth through regulating multiple genes and/or pathways (9, 10). 
Interleukin 6 (IL-6) is an interleukin that mediates the immune 
response, the acute phase response and infl ammation through 
its receptors (IL-6 receptor (IL-6R) and gp130). IL-6 is highly 
up-regulated during infl ammation in response to tissue injury or 
stress and other pro-infl ammatory cytokines (11-13). JAK/STAT 
is activated by the phosphorylation of IL-6 tyrosine residues in 
the cytoplasmic domain of gp130. Thus, IL-6 plays a crucial role 
in the infl ammation-mediated “cancers types”, including prostate, 
breast, gastric, colon, lung and brain due to inducing different 
cytoplasmic tyrosine kinases and transcription factors and thus, 
overexpression of IL-6 is associated with poor prognosis in many 
cancers. Previous studies mentioned that IL-6 mediated STAT3 
activation could be a therapeutic target in gastric, glioblastoma, 
breast, ovarian and lung cancer patients due to mediating muscle 
wasting (14‒20). However, further studies are still needed to clarify 
the association between the changes in IL-6 and STAT-3 levels and 
cancer patients with and without cachexia. 
For this purpose, we for the fi rst time investigated the expres-
sion level of IL-6 and STAT3 in cachectic and non-cachectic cancer 
patients levels with gastric, lung and breast cancer in comparison to 
the control groups, in order to identify the effect of IL-6 signaling 
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on STAT3 activation in cancer cachexia. Furthermore, we explored 
the association between IL-6 mediated the activation of STAT3 and 
gastric, lung and breast cancer patients with and without cachexia.
Materials and methods
Patient population
This study consisted of forty-eight patients (n = 48) with gas-
tric, breast and lung cancer and the patients, were admitted to Sa-
karya University Faculty of Medicine Department of Oncology 
before any surgical or medical procedures. Patients, who had re-
ceived prior treatment before admission were excluded. Eighteen 
of the patients (n = 18) presented with cachexia signs and symp-
toms during the study period and were diagnosed with cachexia 
by corresponding oncology physicians according to diagnostic 
criteria for cachexia. Thirty (n = 30) of the patients did not show 
cachexia symptomatology and maintained a higher BMI than ca-
chectic cancer patients during the study period. The patients were 
categorized into six groups: cachectic patients with gastric (n = 5), 
lung (n = 7) and breast (n = 6) cancer and non- cachectic patients 
with gastric (n = 10), lung cancer (n = 10) and breast cancer (n = 
10) compared with healthy individuals as controls (n = 25). This 
study was approved by the Ethics Committee of Sakarya Univer-
sity (Application number: 16214662/050.01.04/23) and written 
consent was obtained from all the patients included in this study. 
Total RNA isolation and cDNA synthesis
Blood samples from patients were collected and stored at ‒80 °C 
for RNA isolation. Total RNA was isolated by Purelink RNA Mini 
Kit (Invitrogen, Cat. 12183018A) according to the manufacturer’s 
instructions. The concentration of total RNA was analyzed by Qu-
bit RNA Assay Kit and Qubit 4 Fluorometer (Invitrogen/Molecular 
Probes). Then, 100 ng of total RNA was reverse transcribed with High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems). 
Real-time PCR (RT-PCR) analysis
In order to analyze the changes in IL-6 and STAT3 expression 
levels, RT- PCR was performed in 96-well optical reaction plates 
with a StepOnePlus Real-Time PCR Systems (v. 2.0, Applied Bio-
systems) by SYBR Green mix. ACTB was used for the reference 
gene. Primer sequences of IL-6 and STAT3 were shown in Table 1. 
Statistical analysis
Statistical analysis was performed by the SPSS software pack-
age, version 21.0 (SPSS Inc. USA). All data were expressed as the 
mean ± standard deviation (SD) and One-Way ANOVA analysis 
with Post-Tukey test was performed for multiple comparison. 
Univariate ANOVA analysis was used to determine the interac-
tion IL-6 and STAT3 levels with cancer types in terms of cancer 
cachexia. The percent difference was calculated by Δ% formula 
(21). The fold change of the IL-6 and STAT3 levels was statis-
tically analyzed by software (https://www.qiagen.com/tr/shop/
genes-and-pathways/data-analysis-center overview-page/other-
real-time-pcr-probes-or-primers-data-analysis-center/). Statistical 
signifi cance was set at p < 0.05. 
Results
Patients characteristic
From April 2017 to April 2018, 48 cancer patients (18 cachec-
tic and 30 non-cachectic) and 25 healthy controls were included in 
this study and clinical characteristic of cachectic and non-cachectic 
cancer patients included to the study were presented in Tables 2 and 
3. In terms of age, the cachectic and non-cachectic cancer patients 
in each cancer type (gastric, lung and breast cancer patients) and 
controls were similar. The average age of gastric, lung and breast 
cachectic cancer patients was 61.80 ± 10.04, 59.00 ± 3.46 and 45.50 
± 6.22 (mean ± SD), respectively compared with non-cachectic 
patients with gastric, lung and breast cancer (65.90 ± 9.62, 65.40 ± 
5.56 and 54.10 ± 10.4, respectively). BMI was signifi cantly lower 
in cachectic cancer patients than in non-cachectic patients and the 
control. However, cachectic gastric and lung cancer patients indi-
cated a signifi cantly less BMI values than breast cancer patients.






















Age (years) 55.28 ±9.55 61.80 ±10.02 54.40±8.3





















































Weight (kg) 56.35±6.03 76.10±12.32 84.42±5.02
BMI (kg/m2) 17.48±9.79 28.85±7.31 28.11±5.1
Total serum 
protein (g/dL) 6.87±0.58 6.66±1.54 7.4±0.80
Albumin (g/dL) 3.7±9.52 2.3±1.85 4.2±0.30
Tab. 2. Clinical data of cancer patients with cachexia and without ca-
chexia and healthy control subjects.
Guney Eskiler G et al. IL-6 mediated JAK/STAT3 signaling pathway in cancer patients… 
xx
821
IL-6 and STAT3 expression levels in cancer patients with or with-
out cachexia
The expression levels of IL-6 and STAT3 were analyzed in 
gastric (n = 5), lung (n = 7) and breast cancer (n = 6) with ca-
chexia compared with non-cachectic gastric (n = 10), lung (n = 
10) and breast cancer patients (n = 10) and healthy group (n = 25) 
as indicated in Figure 1. In gastric, lung and breast cancer patients 
with cachexia, IL-6 mRNA levels remarkably increased 19.89 ± 
8.25, 5.18 ± 2.81 and 15.33 ± 9.54-fold, respectively (p < 0.01) 
compared to the control group (0.67 ± 0.50). Additionally, a 4.48 
± 2.10 (p = 0.004) and 4.62 ± 3.53-fold (p = 0.026) increase in 
IL-6 expression level was observed in gastric and breast cancer 
patients without cachexia. However, the expression of IL-6 was 
higher in non-cachectic lung cancer patients (8.03 ± 4.38) than in 
cachectic patients (5.18 ± 2.81; p < 0.01). Furthermore, the STAT3 
expression level was signifi cantly higher in gastric (16.67 ± 7.13), 
lung (14.21 ± 11.72) and breast cancer (8.85 ± 3.89) patients with 
cachexia (p < 0.01) compared to the control group (0.78 ± 0.40). 
In cancer patients without cachexia, STAT3 expression level in-
creased by 1.72 ± 0.72 (p = 0.587), 5.83 ± 4.99 (p = 0.037) and 
2.03 ± 0.88-fold (p = 0.102) in gastric, lung and breast cancer 
patients, respectively. 
The association between IL-6 and STAT3 expression levels and 
cancer types
We compared the association between IL-6 and STAT3 ex-
pression levels and patients with cachexia and without cachexia 
in terms of cancer type (gastric, lung and breast). In Figure 2, the 
changes in the expression level of IL-6 was signifi cant between 
gastric and lung cancer patients (p = 0.009) with cachexia. Ad-
ditionally, there was a signifi cant difference between gastric and 
lung cancer patients (p = 0.012) or lung and breast cancer patients 
(p = 0.021) without cachexia according to STAT3 expression level. 
However, there was no signifi cant difference in STAT3 as well as 
IL-6 levels among cachectic cancer patients. 
We performed univariate ANOVA analysis to statistically 
compare cachectic and non-cachectic cancer patients in terms of 
cancer type and IL-6 and STAT3 expression levels. In Table 4, all 
the measured values of IL-6 expression level were statistically 
different in cachectic and non-cachectic gastric, lung and breast 
cancer patients (p < 0.05). Besides, the interaction between cancer 
type and cachexia status was statistically signifi cant (F = 13.127; 
p = 0.001). Thus, IL-6 mRNA level was higher in cachectic lung 
and breast cancer patients than in non-cachectic cancer patients. 
When the ratio of percentage differences in the IL-6 level was 
evaluated between cachectic and non-cachectic patients, there 
was 79.07 %, and 69.86 % increase in gastric and breast cancer 
patients, respectively. However, the expression of IL-6 decreased 
by ‒55.01 % in lung cancer patients with cachexia. When the ra-
tio of percentage differences in the IL-6 level among the types of 
cancer was examined, there was ‒40.09 % ‒11.22 % and 20.60 
% differences between the lung and gastric cancer patients, the 
breast and gastric cancer patients and the breast and lung cancer 
patients, respectively. 
Furthermore, all the measured values of STAT3 mRNA level 














Age (years) 61.80±10.04 59.00±3.46 45.50±6.22 65.90±9.62 65.40±5.56 54.10±10.4































































































Weight (kg) 54.50±4.04 55.29±6.73 58.83±7.44 69.20±9.26 76.5±4.10 83.00±11.71
BMI (kg/m2) 18.90±1.36 19.84±5.64 24.48±3.82 23.80±3.41 25.50±1.82 33.90±6.70
Total serum 
Protein (g/dL) 6.60±0.1 6.64±0.59 7.43±0.35 5.6±2.29 7.08±2.37 7.23±0.51
Albumin (g/dL) 3.28±0.53 3.85±0.06 4.2±0.2 2.06±1.84 2.37±1.70 22.47±2.16
Tab. 3. Characteristics of patients with gastric, lung and breast cancer with cachexia and without cachexia.
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tients in Table 5 (p < 0.05). Additionally, the expression of STAT3 
was statistically different according to the cachectic and non-ca-
chectic status (p < 0.01). The interaction between the cancer type 
and cachexia status was statistically signifi cant (F = 3.204; p = 
0.047). Therefore, STAT3 expression level was higher in cancer 
patients with cachexia than without cachexia. When the ratio of 
percentage differences in the STAT3 level between cachectic and 
non-cachectic patients were investigated, there was 89.68 %, 58.98 
% and 77.06 % increase in the STAT3 levels of gastric, lung and 
breast cancer patients with cachexia, respectively compared with 
Fig. 1. The mRNA level of IL-6 and STAT3 in cachectic and non-cachectic cancer patients compared to the healthy subjects. (A) Gastric, (B) 
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non-cachectic groups. When the ratio of percentage differences in 
the STAT3 level among the types of cancer were examined, there 
was 27.69 %, ‒46.19 % and ‒102.18 % differences between the 
lung and gastric cancer patients, the breast and gastric cancer pa-
tients and the breast and lung cancer patients, respectively. 
Discussion
Cachexia is a multifactorial syndrome observed in advanced-
stage cancer patients, which has a considerable impact on patient 
prognosis and is a major cause of mortality (1‒6). As the molecular 
mechanisms underlying cachexia have not been fully elucidated 
yet, new molecular biomarkers of cancer cachexia are urgently 
explored. In the literature, single nucleotide polymorphism in dif-
ferent genes and cytokines, differentially expressed alternatively 
spliced genes (DASGs), some cytokine (IL-6, and TNF-α) serum 
levels and epigenetic mechanisms have been associated with ca-
chexia in patients with gastric, head and neck, pancreatic and lung 
cancer (22‒32). Additionally, recent studies have indicated that 
high systemic IL-6 levels are linked to worse prognosis in different 
cancer patients (gastric, non-small lung, pancreas etc.) (33‒35). 
However, no prior studies have examined the association IL-6- 
mediated STAT3 activation between cancer patients with cancer 
cachexia, to our knowledge. In the present study, we for the fi rst 
time investigated the association between the expression levels of 
IL-6 and STAT3 in patients with cachectic and non-cachectic gas-
tric, lung and breast cancer. We found that IL-6 mRNA level was 
signifi cantly higher in cachectic gastric and breast cancer patients 
than non-cachectic patients (p < 0.01). Additionally, STAT-3 level 
was remarkably higher in all types of cancer patients with cachexia 
at any TNM stage than non-cachectic patients (p < 0.01). How-
ever, cachectic lung cancer patients indicated lower IL-6 mRNA 
levels than patients without cachexia. Furthermore, there was a 
signifi cant interaction between IL-6 and STAT-3 mRNA level and 
cancer types in terms of cancer cachexia. 
According to an epidemiological analysis of cachexia in pa-
tients with advanced cancer (n = 140), the prevalence of cachexia 
in gastric cancer patients was determined as 76.5 % (36). Infl am-
mation is one of the most important cause in the development of 
gastric cancer. In the infl ammatory process, different cytokines 
Fig. 2. Comparison of IL-6 and STAT3 level in gastric, lung and breast cancer patients according to cachectic and non-cachectic condition (*p 
< 0.05, **p < 0.01).
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such as TNF alpha, IL-1, IL-6, IL-10 induce the activation of intra-
cellular signaling pathways including PI3K/AKT and JAK/STAT 
(37‒40). Additionally, Helicobacter pylori infection is linked to 
an increased risk of developing gastric cancer due to alteration the 
expression level of IL-6 (41, 42). Furthermore, some studies have 
also showed that gastric cancer patients with liver metastases have 
higher levels of IL-6 compared to the healthy controls and high 
serum IL-6 level is associated with tumor invasion, tumor size and 
lymph node metastasis and IL-6 mediated STAT3 activation plays 
a crucial role in increasing tumor size and proliferation of gastric 
cancer (43‒48). Our results demonstrated that IL-6 and STAT3 
expression level were considerably higher in cachectic gastric 
cancer patients levels compared to the non-cachectic and healthy 
control group (p < 0.01). Therefore, our fi ndings suggest that high 
IL-6 and STAT3 mRNA level is associated with the development 
of cachexia and poor prognosis in gastric cancer patients.
In the literature, 45.6 % of patients receiving chemotherapy 
with advanced lung cancer present cancer cachexia signs and 
symptoms. Therefore, cachexia is commonly prevalent in particu-
larly lung and gastrointestinal cancer patients (49). In the study of 
patients with different stages of lung cancer, IL-6 level was up-
regulated compared with healthy subjects (33). Additionally, Miller 
et al (2017) state that IL-6 induces hyperactivation of STAT3 tran-
scription factor via IL-6 cytokine family signaling receptor, gp130, 
and IL-6 regulated STAT3 activation results in cachexia during 
Kras-driven lung carcinogenesis, in vivo (18). In the present study, 
we found that the expression level of IL-6 was higher in cachectic 
and non-cachectic lung cancer patients than in the healthy controls 
(p < 0.05). Interestingly, the mRNA level of IL-6 was lower in lung 
cancer patients with cachexia than that in patients without cachexia. 
According to these fi ndings, the downregulation of STAT3 level in 
cachectic lung cancer patients could be expected. It is known that 
IL-6 induces STAT3 activation via gp130 receptor dimerization, 
which recruits STAT3. STAT3 is then phosphorylated, initiating 
the activation of multiple-genes associated with infl ammation 
(14, 15). However, STAT3 expression is also regulated by differ-
ent cytokines such as: TNFα, IL-11, IL-22, IFNα and IFNβ and 
signaling pathways (NF-κβ) (50‒52). Our fi ndings indicated that 
the expression level of STAT3 was signifi cantly higher in cachec-
tic lung cancer patient than non-cachectic patients (p < 0.01) and 
thus STAT3 could be a therapeutic marker in lung cancer patients. 
However, the changes in STAT3 expression levels could possi-
bly be regulated by different cytokines and signaling pathways. 
Thus, the underlying molecular signaling pathways of STAT3 ac-
tivation and associated cytokines should be further investigated.
Although cachexia is generally observed in pancreatic, gastric, 
colorectal, lung, and head and neck cancer, recent studies have pro-
vided a compelling evidence that there is a relationship between 
advance metastatic breast cancer and cachexia due to a decrease in 
muscle mass and excessive weight loss (53‒55). Recent studies have 
also demonstrated that a high level of IL-6 is associated with cachex-








–X±SD –X±SD –X±SD 
Gastric (X1) 15 19.89±8.25 4.48±2.10 79.07 9.61±8.88
a
4.518 0.017*Lung (X2) 17 5.18±2.81 8.03±4.38 -55.01 6.86±3.98
b
Breast (X3) 16 15.33±9.54 4.62±3.53 69.86 8.64±8.15
ab
Total 48 12.65±9.30 5.71±3.74 8.31±7.17 Grup X Cancer Types Interaction




*p < 0.05; **p < 0.01; a.b: Different letters represent differences between groups; –X: Mean; SD: Standard Deviation; IL-6 value for the control group: 
0.67±0.50; %Δ: (X2-X1)/X2*100








–X± SD –X± SD –X± SD 
Gastric (X1) 15 16.67±7.13 1.72±0.72 89.68 6.71±8.25
ab
4.473 0.015*Lung (X2) 17 14.21±11.72 5.83±4.99 58.98 9.28±9.14
a
Breast (X3) 16 8.85±3.89 2.03±0.88 77.06 4.59±4.14
b
Total 48 13.11±8.69 3.19±3.43 4.81±6.82 Grup X Cancer Types Interaction




*p < 0.05; **p < 0.01; a.b: Different letters represent differences between groups; –X: Mean; SD: Standard Deviation; STAT3 value for the control group: 
0.78±0.40; %Δ: (X2-X1)/X2*100
Tab. 5. Comparison of STAT3 expression level in cachectic and non-cachectic cancer patients.
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and resistance to treatment in advance breast cancer (2, 35, 56). Fur-
thermore, breast cancer patients with high levels of IL-6 compared to 
the heathy control groups indicate cachexia symptoms and are char-
acterized by weight loss (33, 57, 58). Additionally, the activation of 
JAK/STAT, PI3K, and MAPK pathways linked to cancer metastasis, 
tumor cell proliferation, differentiation, apoptosis, angiogenesis 
and invasion have been identifi ed in patients with breast cancer 
(59‒62). In our study, the expression levels of IL-6 and STAT-3 were 
signifi cantly higher in cachectic and non-cachectic breast cancer 
patients than that of the control group, and especially these mRNA 
levels were up-regulated in breast cancer with cachexia. Thus, IL-
6- mediated STAT3 signaling could be a promising biomarker in 
cachectic breast cancer patients as well as gastric cancer patients.
Conclusion 
Our results suggest that STAT3 could be used as a prognostic 
biomarker in gastric, lung and breast cancer patients with cachexia 
and IL-6 mediated STAT3 activation in cachectic gastric and breast 
cancer patients. Additionally, the association between IL-6 and 
STAT3 levels and cancer types in terms of cancer cachexia was 
statistically signifi cant.
However, further studies are required to explore IL6-mediated 
STAT3 activation in larger cohorts of gastric, lung and breast pa-
tients with cachexia or other cancer types. 
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